Benzinga's Top Upgrades, Downgrades For January 2, 2019

Top Upgrades

  • Baird upgraded SunTrust Banks, Inc. STI from Neutral to Outperform. SunTrust shares fell 1 percent to $49.96 in pre-market trading.
  • Stephens upgraded CBS Corporation CBS from Equal-Weight to Overweight. CBS shares rose 0.1 percent to $43.76 in pre-market trading.
  • UBS upgraded Caesars Entertainment Corporation CZR from Sell to Neutral. Caesars rose 0.2 percent to $6.80 in pre-market trading.
  • Susquehanna upgraded Crocs, Inc. CROX from Neutral to Positive. Crocs shares rose 0.3 percent to $26.05 in pre-market trading.
  • Citigroup upgraded Zimmer Biomet Holdings Inc ZBH from Neutral to Buy. Zimmer Biomet fell 0.7 percent to $103.00 in pre-market trading.
  • RBC Capital upgraded Wells Fargo & Co WFC from Underperform to Sector Perform. Wells Fargo shares fell 1.3 percent to $45.50 in pre-market trading.
  • Analysts at JP Morgan upgraded Sirius XM Holdings Inc SIRI from Underweight to Overweight. Sirius XM shares rose 0.4 percent to $5.73 in pre-market trading.
  • Morgan Stanley upgraded Baxter International Inc BAX from Equal-Weight to Overweight. Baxter shares fell 0.8 percent to $65.30 in pre-market trading.
  • Evercore ISI Group upgraded Stryker Corporation SYK from In-Line to Outperform. Stryker shares gained 1.12 percent to close at $156.75 on Monday.
  • Citigroup upgraded Estee Lauder Companies Inc EL from Neutral to Buy. Estee Lauder shares rose 1.2 percent to close at $130.10 on Monday.

 

Top Downgrades

  • Citigroup downgraded Abbott Laboratories ABT from Neutral to Sell. Abbott shares dropped 2.7 percent to $70.39 in pre-market trading.
  • Morgan Stanley downgraded Hologic, Inc. HOLX from Equal-Weight to Underweight. Hologic shares fell 4 percent to $39.45 in pre-market trading.
  • Raymond James downgraded Vertex Pharmaceuticals Incorporated VRTX from Market Outperform to Market Perform. Vertex Pharmaceuticals shares gained 2.66 percent to close at $165.71 on Monday.
  • JP Morgan downgraded AFLAC Incorporated AFL from Overweight to Neutral. Aflac shares dropped 2.1 percent to $44.60 in pre-market trading.
  • Citigroup downgraded Medtronic PLC MDT from Buy to Neutral. Medtronic shares fell 1.1 percent to $90.00 in pre-market trading.
  • Raymond James downgraded BioMarin Pharmaceutical Inc. BMRN from Market Outperform to Market Perform. Biomarin Pharmaceutical shares dropped 2.3 percent to $83.16 in pre-market trading.
  • JP Morgan downgraded Flex Ltd FLEX from Overweight to Neutral. Flex shares fell 0.13 percent to close at $7.61 on Monday.
  • Cowen & Co. downgraded Akamai Technologies, Inc. AKAM from Outperform to Market Perform. Akamai Technologies shares closed at $61.08 on Monday.
  • Baird downgraded Henry Schein, Inc. HSIC from Outperform to Neutral. Henry Schein shares fell 2.5 percent to $76.60 in pre-market trading.
  • Bank of America downgraded CyrusOne Inc CONE from Buy to Neutral. CyrusOne shares rose 1.21 percent to close at $52.88 on Monday.

 

Top Initiations

  • Analysts at Canaccord Genuity initiated coverage on Paratek Pharmaceuticals Inc PRTK with a Buy rating. The price target for Paratek Pharmaceuticals is set to $14. Paratek Pharmaceuticals closed at $5.13 on Monday.
  • Barclays initiated coverage on Moderna Inc MRNA with an Overweight rating. The price target for Moderna is set to $20. Moderna shares closed at $15.27 on Monday.
  • Leerink Swann initiated coverage on Medidata Solutions Inc MDSO with a Market Perform rating. Medidata shares closed at $67.42 on Monday.
  • Canaccord Genuity initiated coverage on Insmed Incorporated INSM with a Buy rating. The price target for Insmed is set to $20. Insmed shares closed at $13.12 on Monday.
  • Morgan Stanley initiated coverage on Moderna Inc MRNA with an Overweight rating. The price target for Moderna is set to $29. Moderna shares closed at $15.27 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesDowngradesInitiationPre-Market OutlookAnalyst RatingsInitiationstop upgrades
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!